Clonidine for anticipatory nausea and vomiting

A pilot study examining dose-toxicity relationships and potential for further study

J. H. Fetting, V. R. Sheidler, Michael Edward Stefanek, J. P. Enterline

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In preparation for studies of noradrenergic activity in anticipatory nausea and vomiting, we performed an open-dose study of clonidine to examine dose-toxicity relationships and indications of antiemetic activity. Nine patients, three each at 0.1, 0.2, and 0.4 mg/day, received clonidine twice a day for 5 days before chemotherapy. Unwanted effects, principally blood pressure reduction, dry mouth, and sedation, accumulated between 4 and 5 μg/kg/day. Four of eight evaluable patients had no anticipatory symptoms on clonidine. It is concluded that clonidine, at a dose of 4 μg/kg/day, might safely probe the role of noradrenergic activity in anticipatory nausea and vomiting.

Original languageEnglish (US)
Pages (from-to)409-410
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number4
StatePublished - Jan 1 1987

Fingerprint

Anticipatory Vomiting
Clonidine
Nausea
Antiemetics
Mouth
Blood Pressure
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clonidine for anticipatory nausea and vomiting : A pilot study examining dose-toxicity relationships and potential for further study. / Fetting, J. H.; Sheidler, V. R.; Stefanek, Michael Edward; Enterline, J. P.

In: Cancer Treatment Reports, Vol. 71, No. 4, 01.01.1987, p. 409-410.

Research output: Contribution to journalArticle

Fetting, J. H. ; Sheidler, V. R. ; Stefanek, Michael Edward ; Enterline, J. P. / Clonidine for anticipatory nausea and vomiting : A pilot study examining dose-toxicity relationships and potential for further study. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 4. pp. 409-410.
@article{01d0006ffe934c73910d1ab261179988,
title = "Clonidine for anticipatory nausea and vomiting: A pilot study examining dose-toxicity relationships and potential for further study",
abstract = "In preparation for studies of noradrenergic activity in anticipatory nausea and vomiting, we performed an open-dose study of clonidine to examine dose-toxicity relationships and indications of antiemetic activity. Nine patients, three each at 0.1, 0.2, and 0.4 mg/day, received clonidine twice a day for 5 days before chemotherapy. Unwanted effects, principally blood pressure reduction, dry mouth, and sedation, accumulated between 4 and 5 μg/kg/day. Four of eight evaluable patients had no anticipatory symptoms on clonidine. It is concluded that clonidine, at a dose of 4 μg/kg/day, might safely probe the role of noradrenergic activity in anticipatory nausea and vomiting.",
author = "Fetting, {J. H.} and Sheidler, {V. R.} and Stefanek, {Michael Edward} and Enterline, {J. P.}",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "71",
pages = "409--410",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Clonidine for anticipatory nausea and vomiting

T2 - A pilot study examining dose-toxicity relationships and potential for further study

AU - Fetting, J. H.

AU - Sheidler, V. R.

AU - Stefanek, Michael Edward

AU - Enterline, J. P.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - In preparation for studies of noradrenergic activity in anticipatory nausea and vomiting, we performed an open-dose study of clonidine to examine dose-toxicity relationships and indications of antiemetic activity. Nine patients, three each at 0.1, 0.2, and 0.4 mg/day, received clonidine twice a day for 5 days before chemotherapy. Unwanted effects, principally blood pressure reduction, dry mouth, and sedation, accumulated between 4 and 5 μg/kg/day. Four of eight evaluable patients had no anticipatory symptoms on clonidine. It is concluded that clonidine, at a dose of 4 μg/kg/day, might safely probe the role of noradrenergic activity in anticipatory nausea and vomiting.

AB - In preparation for studies of noradrenergic activity in anticipatory nausea and vomiting, we performed an open-dose study of clonidine to examine dose-toxicity relationships and indications of antiemetic activity. Nine patients, three each at 0.1, 0.2, and 0.4 mg/day, received clonidine twice a day for 5 days before chemotherapy. Unwanted effects, principally blood pressure reduction, dry mouth, and sedation, accumulated between 4 and 5 μg/kg/day. Four of eight evaluable patients had no anticipatory symptoms on clonidine. It is concluded that clonidine, at a dose of 4 μg/kg/day, might safely probe the role of noradrenergic activity in anticipatory nausea and vomiting.

UR - http://www.scopus.com/inward/record.url?scp=0023182423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023182423&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 409

EP - 410

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -